San Raffaele-Telethon gene therapy spinout Genespire has picked up series A funding from Sofinnova Partners to target inherited metabolic diseases and primary immunodeficiencies.

Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Liberty Global Ventures, Gradient Ventures, Motorola Solutions Venture Capital, Numbase and KDDI Open Innovation Fund all backed the smart contact lens developer's series B-1 round.

Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has formed a strategic partnership with Microport in connection with a $43.4m round.

UT Southwestern has formed central nervous system diseases treatment developer Taysha Gene Therapies with executives who previously worked for OSU's Avexis.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

NetScientific's pre-tax loss was halved to $6.5m during 2019, and the firm also reported improved cash availability.

Boehringer Ingelheim Venture Fund co-led a series A round set to drive clinical work on UC Berkeley-founded Actym Therapeutics' immunotherapy pipeline.

Novo and Pivotal BioVenture Partners both invested as the lung disease therapy developer took its overall funding close to $100m.